# US 2025/0152534 A1 · Method of treatment of parkinson’s disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2025/0152534 A1
- Document ID: US20250152534A1
- Status: Published application
- Kind: A1
- Application number: 18/748,756
- Filed: 2024-06-20
- Published: 2025-05-15
- Earliest claimed: 2020-11-17
- Assignees: NeuroDerm, Ltd.
- Applicants: NeuroDerm, Ltd.
- Inventors: Tal Birnberg; Liat Adar; Itay Perlstein
- Web page: https://patentgrep.com/patent/US20250152534A1

## CPC

- A61K 31/198: Alpha-amino acids, e.g. alanine or edetic acid [EDTA] (betaine A61K31/205; proline A61K31/401; tryptophan A61K31/405; histidine A61K31/4172; peptides not degraded to individual amino acids A61K38/00)
- A61K 9/0019: {Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner (non-active ingredients are additionally classified in A61K47/00)}
- A61K 9/0021: {Intradermal administration, e.g. through microneedle arrays or needleless injectors}
- A61K 9/0053: {Mouth and digestive tract, i.e. intraoral and peroral administration}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/4808: {characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release (capsules filled with granules or microparticles A61K9/16; filled with microcapsules or coated microparticles A61K9/50; with mixture of different granules, microcapsules, (coated) microparticles A61K9/5084)}
- A61K 9/4858: {Organic compounds}
- A61K 47/183: {Amino acids, e.g. glycine, EDTA or aspartame}
- A61P 25/00: Drugs for disorders of the nervous system
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Disclosed is a method for the treatment of a neurological or movement disorder, e.g., Parkinson's disease, in an individual in need thereof, by parenteral administration of levodopa and a dopa decarboxylase inhibitor (DDCI), such as carbidopa, benserazide or any combination thereof, concomitantly with oral administration of levodopa, a DDCI, such as carbidopa, benserazide, or any combination thereof.

## Claims

### Claim at position 1

-55. (canceled)

### Claim 56

A method for treatment of a neurological or movement disorder in a patient in need thereof, said method comprising:
parenterally administering to the patient a first pharmaceutical composition comprising:
a) levodopa, a levodopa salt, a levodopa prodrug, or any combination thereof; and
b) a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug, or any combination thereof;
and, concomitantly,
orally administering to the patient a second pharmaceutical composition comprising an active agent selected from the group consisting of levodopa, a levodopa salt, a levodopa prodrug, a dopa decarboxylase inhibitor (DDCI), a DDCI salt, a DDCI prodrug, and any combination thereof.

### Claim 57 (depends on 56)

The method according to claim 56, wherein the DDCI is carbidopa, benserazide or any combination thereof.

### Claim 58 (depends on 56)

The method according to claim 56, wherein the DDCI is the first pharmaceutical composition is the same as the DDCI in the second pharmaceutical composition.

### Claim 59 (depends on 56)

The method according to claim 56, wherein the DDCI is the first pharmaceutical composition is different from the DDCI in the second pharmaceutical composition.

### Claim 60 (depends on 56)

The method according to claim 56, wherein the second pharmaceutical composition comprises levodopa and a DDCI.

### Claim 61 (depends on 56)

The method according to claim 56, wherein the DDCI is carbidopa.

### Claim 62 (depends on 56)

The method according to claim 56, wherein said first pharmaceutical composition is administered subcutaneously, transdermally, intradermally, intravenously, intramuscularly, intratracheally, intranasally, intrathecally, intragastrically or intraduodenally.

### Claim 63 (depends on 56)

The method according to claim 56, wherein said first pharmaceutical composition is administered subcutaneously.

### Claim 64 (depends on 56)

The method according to claim 56, wherein said first pharmaceutical composition is administered to said patient in need thereof via one or more sites.

### Claim 65 (depends on 56)

The method according to claim 56, wherein said neurological or movement disorder is Parkinson's disease; secondary parkinsonism, such as drug-induced secondary parkinsonism, neuroleptic induced parkinsonism, postencephalitic parkinsonism, and vascular parkinsonism; motor fluctuations; neurodegenerative disorders; dyskinesia; reduced dopamine levels in the brain; levodopa induced dyskinesia; rapid eye movement sleep behavior disorder (RBD); dystonia; morning akinesia; tremor symptoms, such as essential tremor and drug-induced tremor; myoclonus; chorea, such as drug induced chorea; tics, such as drug induced tics and organic tics; drug induced movement disorder; drug induced akathisia; restless legs syndrome (RLS); stiff-man syndrome; benign shuddering attacks; malignant neuroleptic syndrome; Huntington's disease; Shy-Drager syndrome; brain injury induced conditions, such as carbon monoxide or manganese intoxication; or any combination thereof.

### Claim 66 (depends on 56)

The method according to claim 56, wherein said first pharmaceutical composition is administered substantially continuously.

### Claim 67 (depends on 56)

The method according to claim 56, wherein said second pharmaceutical composition is administered 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 times a day.

### Claim 68 (depends on 56)

The method according to claim 56, wherein said second pharmaceutical composition is administered when symptoms from said neurological or movement disorder require said administration.

### Claim 69 (depends on 56)

The method according to claim 56, wherein the second pharmaceutical composition is administered at predefined times, predefined intervals, or both.

### Claim 70 (depends on 56)

The method according to claim 56, wherein the second pharmaceutical composition is administered more than once, wherein the administered dose is the same at all administrations.

### Claim 71 (depends on 56)

The method according to claim 56, wherein the second pharmaceutical composition is administered more than once, wherein the administered dose differs in at least two administrations.

### Claim 72 (depends on 56)

The method according to claim 56, wherein the second pharmaceutical composition is administered in a dose of between about 25 mg levodopa and about 400 mg levodopa, in each administration.

### Claim 73 (depends on 56)

The method according to claim 56, wherein the first pharmaceutical composition comprises levodopa, carbidopa and arginine.

### Claim 74 (depends on 56)

The method according to claim 56, wherein the first pharmaceutical composition comprises levodopa, carbidopa, arginine and at least one antioxidant.

### Claim 75 (depends on 56)

The method according to claim 56, wherein the first pharmaceutical composition comprises levodopa, carbidopa, arginine and at least two antioxidants.
